Clinical trial

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

NCT06081686

Study summary

ClinicalTrials.gov

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Phase I:[177Lu]Lu-XT033 Injection Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Phase II:[177Lu]Lu-XT033 Injection Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-09-13

PhasePHASE1 / PHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Phase I:[177Lu]Lu-XT033 InjectionDRUG

Phase II:[177Lu]Lu-XT033 InjectionDRUG

Sponsors & collaborators

Sinotau Pharmaceutical Grouplead sponsor

Mapped research locations

BeijingBeijing Municipality, China1 ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06081686 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.